Provided by Tiger Trade Technology Pte. Ltd.

NRX Pharmaceuticals Inc.

3.45
-0.1100-3.09%
Volume:898.03K
Turnover:3.15M
Market Cap:149.37M
PE:-4.45
High:3.61
Open:3.52
Low:3.44
Close:3.56
52wk High:5.06
52wk Low:1.62
Shares:43.30M
Float Shares:36.46M
Volume Ratio:1.04
T/O Rate:2.46%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7754
EPS(LYR):-1.3374
ROE:-682.61%
ROA:-63.99%
PB:-878.65
PE(LYR):-2.58

Loading ...

NRX Pharmaceuticals Advances Robotic-Enabled Transcranial Magnetic Stimulation Combined With Neuroplastic Therapy for Military and First Responder Applications

THOMSON REUTERS
·
Apr 15

NRX Pharmaceuticals Inc: Development Initiative to Be Conducted Through R&D Unit NRX Defense Systems, in Partnership With Zeta Surgical

THOMSON REUTERS
·
Apr 15

NRX Pharmaceuticals (Nasdaq:Nrxp) Announces Appointment of Glenn Tyson as the Company’s First Chief Commercial Officer

THOMSON REUTERS
·
Apr 13

Press Release: NRx Pharmaceuticals (Nasdaq:NRXP) Announces Appointment of Glenn Tyson as the Company's first Chief Commercial Officer

Dow Jones
·
Apr 13

NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Labeling Alignment for NRx’s Preservative-Free Ketamine Application

GlobeNewswire
·
Apr 06

NRx unit Hope Therapeutics partners with Emobot to deploy AI depression monitoring networkwide

Reuters
·
Mar 30

Hope Therapeutics, an NRX Pharmaceuticals Subsidiary (Nasdaq:Nrxp), Announces Strategic Partnership With Emobot to Integrate Its AI-Powered “Depression Thermometer” Across Its Interventional Psychiatry Network

THOMSON REUTERS
·
Mar 30

Analysts Are Bullish on Top Healthcare Stocks: NRX Pharmaceuticals (NRXP), Rezolute (RZLT)

TIPRANKS
·
Mar 25

Nrx Pharmaceuticals: Extensive Clinical, Regulatory, and Financial Risks Make Shares Highly Speculative

TIPRANKS
·
Mar 25

NRX Pharmaceuticals held annual shareholder meeting, investors approved incentive plan amendment

Reuters
·
Mar 25

NRX Pharmaceuticals Price Target Maintained With a $25.00/Share by BTIG

Dow Jones
·
Mar 25

NRX Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 24

NRx Pharmaceuticals (Nasdaq:NRXP) Reports Full-Year 2025 Results and Highlights Key Regulatory and Commercial Progress

GlobeNewswire
·
Mar 24

NRX Pharmaceuticals Q4 EPS $0.20 Up From $(0.77) YoY, Sales $983.000K

Benzinga Earnings
·
Mar 24

NRx Pharmaceuticals FY 2025 net loss was USD 29 million as interest expense rose 192% to USD 1 million

Reuters
·
Mar 24

NRX Pharmaceuticals Inc expected to post breakeven results a share - Earnings Preview

Reuters
·
Mar 20

NRx Pharmaceuticals to host full-year 2025 financial results conference call

Reuters
·
Mar 19

NRX Pharmaceuticals, Inc. (Nasdaq: Nrxp) to Report Full Year 2025 Financial Results and Provide a Corporate Update on March 24, 2026

THOMSON REUTERS
·
Mar 19

FDA finds no bioequivalence deficiencies in NRX Pharmaceuticals’ preservative-free ketamine ANDA review

Reuters
·
Mar 17

NRX Pharmaceuticals (Nasdaq:Nrxp) Announces FDA Bioequivalence Determination by Office of Generic Drugs for NRX’s Preservative-Free Ketamine Application

THOMSON REUTERS
·
Mar 17